Factor XIII Deficiency

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Factor XIII (FXIII) deficiency is a rare bleeding disorder that presents with symptoms spanning from delayed umbilical cord separation to intracranial hemorrhage. In its activated state, FXIII plays a pivotal role in stabilizing clots and facilitating the cross-linking of the fibrin polymer, thereby ensuring effective hemostasis. Routine coagulation assessments, such as prothrombin time and activated partial thromboplastin time, yield normal results, misleadingly indicating hemostatic normalcy. Individuals with FXIII deficiency may encounter life-threatening bleeding episodes, underscoring the importance of maintaining a heightened level of suspicion.

The acquired FXIII deficiency typically arises from factors such as hyperconsumption, hemodilution, and decreased synthesis and is more prevalent than the congenital form. In rare instances, individuals with acquired FXIII deficiency may generate autoantibodies targeting FXIII subunits. Conversely, most patients with the congenital variant display a deficiency in the A subunit. In addition, FXIII is instrumental in various physiological processes such as wound healing, phagocytosis by macrophages, tissue repair, and bacterial immobilization and clearance.

Diagnosis involves a stepwise approach, incorporating family history, personal responses to hemostatic challenges, and strategic laboratory testing. Although prophylactic and therapeutic treatment options exist, their limitations may include high cost, limited availability, infection risk, and administration-related complications. This activity discusses the etiology, evaluation, and treatment of FXIII deficiency, emphasizing the pivotal role of the interprofessional healthcare team in identifying and managing this condition.

Objectives:

  • Identify patients presenting with symptoms suggestive of Factor XIII deficiency through comprehensive clinical evaluation and thorough medical history assessment.

  • Implement prophylactic and therapeutic treatment strategies for patients diagnosed with Factor XIII deficiency, considering factors such as FXIII activity levels, bleeding severity, and individual patient needs, to optimize hemostasis and prevent life-threatening bleeding episodes.

  • Select alternative treatment options, such as cryoprecipitate and fresh frozen plasma, for effective hemostatic management when Factor XIII replacement products are unavailable or contraindicated.

  • Collaborate with healthcare team members to ensure comprehensive care for patients with Factor XIII deficiency by communicating effectively with them about the nature of FXIII deficiency, thereby minimizing the risk of bleeding complications and optimizing long-term outcomes.

Introduction

Factor XIII (FXIII) deficiency is a rare bleeding disorder that presents with symptoms spanning from delayed umbilical cord separation to intracranial hemorrhage. In its activated state, FXIII plays a pivotal role in stabilizing clots and facilitating the cross-linking of the fibrin polymer, thereby ensuring effective hemostasis.

FXIII deficiency can manifest in both congenital and acquired forms, leading to reduced clot stability and abnormal bleeding tendencies. The acquired FXIII deficiency typically arises from factors such as hyperconsumption, hemodilution, and decreased synthesis and is more prevalent than the congenital, autosomal recessive form. In rare instances, individuals with acquired FXIII deficiency may generate autoantibodies targeting FXIII subunits. Conversely, in the congenital variant of FXIII deficiency, which comprises A (FXIII-A) and B (FXIII-B) subunits, most patients typically display a deficiency of the A subunit. 

Beyond its role in clotting, FXIII is instrumental in various physiological processes such as wound healing, phagocytosis by macrophages, tissue repair, and bacterial immobilization and clearance. The condition presents a complex genetic landscape with over 100 identified mutations in the FXIII-A gene.

Clinical manifestations of FXIII deficiency include delayed separation of the umbilical cord and bleeding from the umbilical stump in neonates. Moreover, patients may present with intracranial hemorrhage without significant trauma, impaired wound healing, menorrhagia, hemarthrosis, and spontaneous miscarriages in early pregnancy.

Diagnosis of FXIII deficiency involves a stepwise approach, incorporating family history, personal responses to hemostatic challenges, and strategic laboratory testing. Given its rarity, clinicians must remain vigilant in identifying this disorder. Although prophylactic and therapeutic options are available, their restricted availability, high cost, infection risk, and potential administration-related complications present challenges. Clinicians must navigate these complexities to deliver comprehensive care to individuals with FXIII deficiency, highlighting the importance of a multidisciplinary approach for optimal patient management.

Etiology

Congenital FXIII Deficiency

FXIII-A is primarily produced in the hematopoietic cells, whereas FXIII-B production occurs in hepatocytes. Assembly occurs in the plasma. Once fully formed, FXIII consists of a dimer of catalytic A subunits (FXIII-A2) and a dimer of carrier or inhibitory B subunits (FXIII-B2), forming a heterotetrameric complex FXIIIA2B2. Acquired forms of FXIII deficiency are more prevalent than the congenital forms. Congenital FXIII deficiency has an autosomal recessive pattern of transmission. Ninety-five percent of patients with the congenital form carry variations in the F13a1 gene located on chromosome arm 6p24-25 encoding the FXIII-A subunit.[1]

To date, researchers are aware of 153 genetic variations associated with FXIII deficiency, with missense mutations occurring in over 50% of cases.[2] In addition, the F13b gene, located on chromosome arm 1q31-32.1 and encoding the FXIII-B subunit, can be affected, with missense mutations being the most prevalent.[3] Currently, nearly 16 mutations are known in the B subunit.[3] The B subunit acts as a carrier for subunit A, preventing spontaneous activation. Hence, a deficiency or defect of the subunit B makes the FXIIIA2B2 complex unstable, leading to a relative deficiency of subunit A. Patients with a B subunit deficiency have a less severe bleeding phenotype.[4]

Acquired FXIII Deficiency 

Acquired FXIII deficiency can arise secondary to autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. In these cases, affected patients produce autoantibodies targeting FXIII. In addition, medications such as isoniazid and conditions such as monoclonal gammopathy of undetermined significance have been implicated in causing FXIII deficiency.[5][6][7]

Hyperconsumption of FXIII can occur due to various factors such as surgery, disseminated intravascular coagulation, inflammatory bowel disease, Henoch-Schönlein purpura, sepsis, leukemia, and thrombosis. Furthermore, hyposynthesis resulting from liver disease and certain medications, including valproic acid, chemotherapeutic agents, and tocilizumab (an anti-interleukin-6 receptor antibody) can also lead to FXIII deficiency.[8] 

Epidemiology

FXIII deficiency, a rare condition, is estimated to have a frequency of 1 in 2 to 3 million live births. The prevalence of this condition tends to be higher in regions such as Iran, where consanguinity rates are elevated. However, there is no discernible variation in prevalence based on ethnicity or race globally.[9][10][11] Notably, prevalence rates may change with increased awareness, improved laboratory testing, and the increased global use of isoniazid worldwide for tuberculosis treatment.

Pathophysiology

FXIII deficiency results in defective cross-linking of fibrin, rendering individuals susceptible to delayed bleeding once the initial hemostatic plug becomes overwhelmed. FXIII is a zymogen, or inactive precursor, which transforms into an enzyme upon activation by another enzyme. FXIII-A is the pro-transglutaminase that undergoes catalysis to become the active transglutaminase. FXIII-B acts as a carrier and regulatory protein for the A subunit, which is inherently unstable in plasma. Half of FXIII-B circulates in plasma, bound to FXIII-A, while the remainder circulates as FXIII-B2. Cellular FXIII-A exists primarily as FXIII-A2 and is present in macrophages, monocytes, megakaryocytes, and platelets.

FXIII-A introduces covalent bonds between fibrin monomers, resulting in a stiff and compact fibrin clot, which is protected from degradation by α-2 antiplasmin and thrombin-activatable fibrinolysis inhibitor. Platelet-bound FXIII, present on activated platelet surfaces, aids in clot stabilization and retraction, essential processes for wound healing. Furthermore, FXIII plays a pivotal role in wound healing by cross-linking proteins within the extracellular matrix, including fibronectin, vitronectin, thrombospondin, and collagen, and by promoting cellular signaling in leukocytes and endothelial cells.[9] FXIII causes vascular endothelial growth factor receptor 2 (VEGFR-2) activation by binding to αVβ3-integrin, leading to endothelial cell proliferation, survival, and angiogenesis.[9] FXIII-A notably exhibits a positive effect on angiogenesis.[9]

The function of FXIII extends beyond hemostasis to encompass critical functions in wound healing, tissue repair, extracellular matrix deposition, osteoblastic differentiation, and regulation of immune responses, both at cellular and humoral levels. The fibrin clot, aided by FXIII, is a crucial component of innate immunity, with FXIII-A enhancing the proliferation and migration of monocytes. Furthermore, FXIII-A contributes to regulating preadipocyte differentiation and modulating insulin signaling by facilitating the assembly of plasma fibronectin into the extracellular matrix, potentially influencing adipogenesis.

History and Physical

Homozygous individuals may exhibit delayed detachment and bleeding of the umbilical cord, hemarthrosis, intracranial hemorrhage, heavy menstrual bleeding, recurrent early pregnancy loss, delayed postoperative bleeding, and prolonged bleeding after trauma or surgery.[12] Caregivers may notice easy bruising and soft tissue bleeding when a child begins to ambulate or during episodes of emotional distress. In contrast, heterozygous patients typically remain asymptomatic. Umbilical cord bleeding is reported in up to 80% of neonates, often occurring within the first 3 weeks after birth.[9][13] The extent of bleeding usually correlates with plasma FXIII levels; symptoms are often observed in patients with FXIII levels below 5%. The risk of experiencing significant spontaneous bleeding increases notably when FXIII factor activity falls below 15%. Individuals with undetectable FXIII levels typically present symptoms during the neonatal period.

Thirty percent of neonates with severe FXIII deficiency, or FXIII level less than 1%, experience spontaneous, life-threatening intracranial hemorrhage, a significantly higher incidence compared to hemophilia A and B.[14][15] Posttraumatic intracranial hemorrhage is frequently recognized as the initial indicator of FXIII deficiency in older children, with one-third experiencing recurrence. Recurrent intracranial hemorrhage is associated with higher mortality in patients with FXIII deficiency.[16]

Acquired FXIII deficiency is rare, and its presentation varies based on the underlying cause.[17] In cases where it is immune-mediated, acquired FXIII deficiency often presents with spontaneous bleeding in the subcutaneous or intramuscular compartments.[5] This condition predominantly affects individuals aged 70 or older who have underlying conditions such as SLE, rheumatoid arthritis, and leukemia. For further information regarding underlying conditions, please refer to the Etiology section of this article.[5] 

Evaluation

The evaluation for potential bleeding disorders typically begins with a comprehensive assessment of personal and family medical histories. In instances of a family history of a bleeding disorder, clinicians should examine the family pedigree to ascertain the inheritance pattern. Subsequently, factor activity levels of the neonate should be tested, preferably utilizing cord blood. Pregnant patients may choose to undergo chorionic villous sampling between 10 and 12 weeks of gestation or amniocentesis between 16 and 20 weeks of gestation to obtain fetal cells for DNA analysis in linkage studies. If fetal DNA is unobtainable, clinicians may opt for a fetoscopy to collect fetal blood at 20 weeks of gestation. Given the 0.5% risk of maternal-fetal complications and the 1% to 6% risk of fetal death associated with fetoscopy, thorough genetic and obstetric counseling is essential before these procedures.

Although routine clotting tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR), help diagnose many other factor deficiencies, they do not detect FXIII deficiency, as FXIII plays a role after fibrin generation. Consequently, these tests typically yield normal results in individuals with FXIII deficiency.[18] Evaluating FXIII deficiency necessitates specialized laboratory tests, including the clot solubility test, FXIII activity assay, FXIII antigen assay, inhibitor assay, and genetic analysis.

As thromboelastography (TEG) lacks standardization across different institutions, it is, therefore, not considered a reliable diagnostic tool for this condition. Although growing evidence suggests that TEG is more sensitive than the solubility tests,[19] further prospective studies are required to validate this observation.

All other FXIII deficiencies will have associated abnormal aPTT and PT if the following conditions exist: 

  • Isolated elevation of PT and test FVII activity.
  • Isolated elevation of aPTT, test FVIII, FIX, and FXI activities.
  • Elevated PT and aPTT, test FV, FX, FII or thrombin, and fibrinogen.
  • Normal PT and aPTT test FXIII.

Clot Solubility Test

The benefits of the clot solubility test include its simplicity, cost-effectiveness, and the absence of specialized equipment. This test evaluates clot solubility in either 5M urea or 1% monochloroacetic acid. If clot lysis occurs within a few hours, severe FXIII deficiency is likely, provided that fibrinogen levels are qualitatively and quantitatively within the reference range. However, the test's clinical reliability is limited by its false-positive rate. The acetic acid assay is faster and more sensitive than the urea solubility test but lacks specificity.[20] 

Various scenarios may influence the results of the clot solubility test, including: 

  • Hypofibrinogenemia or dysfibrinogenemia can lead to false-positive outcomes on the 5M urea test. Therefore, clinicians should assess patients for hypofibrinogenemia using tests such as thrombin time, reptilase time, fibrinogen assay, and fibrinogen activity before diagnosing FXIII deficiency.[21]
  • High levels of pepsinogen, which can be present in certain gastric disorders, can potentially generate false-positive outcomes on the acetic acid test.[22]

The clot solubility test is fraught with additional limitations. The clot sensitivity test lacks adequate sensitivity and specificity and may underestimate the degree of FXIII deficiency. Furthermore, the test cannot reliably identify patients with mild or moderate FXIII deficiency, and heterozygous carriers may go undetected. Standardization of the clot solubility test across various laboratories is lacking, and its usage is uncommon in developed countries. However, this test is still widely popular in developing countries where alternative assays may be unavailable due to its low cost. No standard guidelines exist for the utilization of the clot solubility test. An alternative diagnostic approach involves using 2 different assays, each utilizing distinct clotting and solubilizing agents, and conducting both tests concurrently. If 1 test yields a positive result, further investigations are warranted to assess for FXIII deficiency.[23] 

Quantitative Assays

Quantitative or functional assays, if available, are the preferred initial tests to diagnose FXIII deficiency. 

Ammonia release assay: The ammonia release assay is a quick and efficient method for assessing FXIII activity. This assay operates based on the release of ammonia during the transglutaminase reaction and quantifies FXIII activity by measuring the photometric absorbance at a wavelength of 340 nm. FXIII activity leads to the release of ammonia, which in turn converts nicotinamide adenine dinucleotide phosphate plus hydrogen (NADPH) or nicotinamide adenine dinucleotide plus hydrogen (NADH) to NAD+ or NADP+. The assay determines FXIII activity by measuring the consumption of NADPH. However, because FXIII independently releases ammonia, this test may overestimate FXIII activity and report falsely elevated levels. To address this issue, manufacturers include a plasma blank in the kit, which corrects this phenomenon and ensures an accurate reading of FXIII activity.[10]

Amine incorporation assay: These tests use fluorescent, radiolabeled, or biotinylated amines covalently bound to a glutamine residue of the substrate measured after the protein fraction releases unbound amines. Although a more sensitive test than the ammonia release assay, this assay is not standardized, lacks validity, and is time-consuming.[10] 

Isopeptide assay: The amine incorporation assay utilizes fluorescent, radiolabeled, or biotinylated amines that are covalently bound to a glutamine residue of the substrate. The unbound amines are measured after the protein fraction releases them. Although this assay is more sensitive than the ammonia release assay, it is time-consuming and lacks standardization and validity.

Immunological Assays

Immunological assays can distinguish between FXIII-A, FXIII-B, and the FXIIIA2B2 complex, thereby identifying the type of deficiency present. However, these assays cannot detect rare forms of FXIII deficiency, such as type II defects, where the FXIII-A subunit is present but functionally inactive. An example of a widely utilized immunoassay is the enzyme-linked immunoassay (ELISA). The R-ELISA (Reanal-ker, Budapest, Hungary) is a single-step sandwich ELISA using an anti-FXIII-A primary antibody and an anti-FXIII-B secondary antibody. This assay effectively eliminates interference from free FXIII-B subunits and fibrinogen, allowing for determining FXIII concentrations as low as 0.001 IU/mL. Electroimmunoassays and radioimmunoassays, although available, are less commonly used due to their lack of standardization and cumbersome procedures. 

FXIII Inhibitor Assays

Inhibitor assays are necessary for patients suspected of developing antibodies to FXIII. Patients can develop the following 2 types of antibodies:

  • Neutralizing autoantibodies against FXIII-A, which are typically not detected by mixing studies.
  • Non-neutralizing inhibitors, generally immunoglobulins IgG or IgM antibodies, which can be detected through ELISA assays.[24][25]

These assays are conducted only in select countries and institutions where the necessary tests are available. With over 1000 polymorphisms present in both FXIII subunits, it is impractical to map the entire gene in all patients. Evidence suggests that these polymorphisms vary based on ethnicity.[2] Consequently, many countries and institutions prioritize testing for the most prevalent polymorphisms in their respective populations.[26][27] 

Treatment / Management

All neonatal invasive procedures, such as circumcision, should be postponed until the diagnosis of FXIII deficiency can be confirmed or excluded. Treatment options should be tailored to the specific needs of each patient. 

Clinicians use FXIII replacement products to treat and prevent acute bleeding in patients with FXIII deficiency. Two such products are catridecagog, a recombinant FXIII-A subunit (marketed as Tretten by Novo Nordisk), and FXIII purified from human plasma (known as Fibrogammin and Fibrogammin-P in Europe, South America, and Asia, and Corifact in the United States).[28][29][30] The plasma-derived product has both subunits A and B, making it a universally acceptable product that can control bleeding in patients regardless of a mutation in subunit A or B.[30] 

Recombinant FXIII-A (rFXIII-A2) contains only FXIII-A, making it specific to most patients with FXIII deficiency. In a multinational, open-label, single-arm phase 3 trial, prophylactic administration of rFXIII-A2 to 41 patients with congenital FXIII-A deficiency resulted in a decline in the annual rate of bleeding from 0.138 compared to 2.91 annual bleeds per patient historically treated on demand.[14] In addition, findings from the MENTOR-2 trial indicate that surgical patients receiving prophylactic doses of 35 IU/kg of rFXIII-A2 experienced annual bleeding rates of 0.043 per patient, with a mean yearly spontaneous bleeding rate of 0.011 per patient. All study participants remained in the trial and tolerated the drug well.[31] The efficacy of rFXIII-A2 was further confirmed in a real-world study conducted in Italy, demonstrating effective control over a broad range of dosing schedules.[32]

When FXIII replacement products are unavailable, cryoprecipitate and fresh frozen plasma (FFP) are suitable alternatives. Solvent-detergent treated FFP is ideal if available. Cryoprecipitate contains approximately 20% to 30% of the original quantity of FXIII as plasma.[33] Although many European countries have withdrawn cryoprecipitate due to safety concerns such as pathogen transfer, it remains available in the United States, Canada, and many other countries.[34] 

The average content of FXIII in FFP varies between 0.5 and 1.5 U/mL.[35] Compared to FFP, cryoprecipitate has a higher enrichment of FXIII.[35][36] However, 1 bag of cryoprecipitate yields lower than that of a bag of FFP.[35] FFP may be preferred when infusion volume is not a significant consideration.

Acute Bleeding

The treatment goal is to attain FXIII activity levels greater than 5%. Higher targets may be required for severe, life-threatening bleeding episodes. A single dose of replacement product is typically sufficient to achieve therapeutic objectives. The dosing for patients experiencing acute bleeding is outlined as follows:

  • Recombinant FXIII-A subunit: 35 IU/kg
  • Plasma-derived FXIII concentrate: Corifact 40 IU/kg; Fibrogammin and Fibrogammin-P 10 to 20 IU/kg
  • Fresh frozen plasma: 15 to 20 mL/kg
  • Cryoprecipitate: 1 bag per 10 kg

Perioperative Management

The dosing remains consistent for patients experiencing acute bleeding. The usual therapeutic aim is to achieve FXIII activity levels exceeding 5%. Nonetheless, bleeding may still arise during surgical procedures or trauma in affected patients, necessitating higher activity levels.[37] If the patient has received a routine prophylactic dose within 7 days before a surgical procedure, additional treatment may not be required. However, if not, administration of FXIII concentrate is warranted. Given the long half-life of FXIII, ranging from 11 to 14 days, a single dose is typically adequate.

Pregnant patients with FXIII deficiency: Pregnant patients with severe FXIII deficiency face significant risks, necessitating FXIII replacement therapy for successful pregnancy outcomes. Initiation of replacement therapy should ideally occur by 5 weeks of gestation to mitigate the risk of miscarriage.[38] FXIII activity levels should be maintained above 2% to 3%, with levels greater than 10% being optimal. Dosing typically involves a regimen of 250 IU/week up to 22 weeks of gestation, followed by an increase to 500 IU/week from 23 weeks gestation until the onset of labor. In addition, pregnant patients are administered 1000 IU at the onset of labor to attain factor activity levels exceeding 30% for delivery. An alternative dosing schedule involves 10 IU/kg every 2 weeks throughout pregnancy.[39][40]

Prophylaxis: Prophylactic therapy is warranted for patients with FXIII activity levels below 5% or a history of recurrent bleeding episodes. The dosing regimen mirrors that used for acute bleeding management. Patients diagnosed with FXIII-B deficiency should be treated with plasma-derived factor concentrate. Alternatively, FFP and cryoprecipitate can be considered as viable options. Prophylactic dosing intervals typically occur every 20 to 30 days to sustain trough FXIII levels above 5%.

Patients with acquired FXIII deficiency: For patients diagnosed with acquired FXIII deficiency, treatment strategies may involve FXIII replacement therapy, antifibrinolytics administration, and inhibitor eradication. Mild inhibitors may respond to steroid therapy alone, while more potent inhibitors may necessitate B-cell-directed therapy, frequently using rituximab. In addition, plasma exchange has demonstrated efficacy in the short-term removal of FXIII inhibitors.[41]

Differential Diagnosis

All bleeding disorders, including factor deficiencies and platelet dysfunction syndromes, can mimic FXIII deficiency. The following list outlines potential differential diagnoses:

  • Inherited afibrinogenemia or dyshypofibrinogenemias, α2 -plasmin inhibitor deficiency, plasminogen activator inhibitor-1 deficiency, hemophilia A or B, and type III von Willebrand disease.
  • Platelet dysfunction disorders such as Glanzmann thrombasthenia, Bernard Souilier syndrome, and von Willebrand disease types I and II.
  • Additional coagulation factor deficiencies, including FII, FV, FVII, FX, and FXI.
  • Acquired causes of FXIII deficiency, including malignancy, autoimmune disorders, medications, hyperconsumption, disseminated intravascular coagulation (DIC), and liver disease.

Prognosis

Congenital FXIII deficiency is extremely rare, and acquired FXIII deficiency is even rarer. Patients receiving replacement therapy can typically expect an average life expectancy, although there is a lack of large-scale studies on mortality rates. In untreated individuals, intracranial hemorrhage stands as the primary cause of death.[25] 

Approximately 30% of cases of central nervous system bleeding experience recurrence, with approximately 50% of these instances resulting in fatality. However, the severity of FXIII deficiency can vary among families. The development of FXIII inhibitors, whether alloantibodies or autoantibodies, is associated with significant morbidity and mortality.

Complications

Complications associated with FXIII deficiency are most common in untreated patients. The following is a list of potential complications related to FXIII deficiency:

  • Umbilical bleeding, intracranial hemorrhage, recurrent fetal loss, hemarthrosis, delayed postoperative or posttraumatic bleeding, pathogen transmission from plasma-derived products, development of FXIII inhibitors, and transfusion reactions.
  • Central venous catheter-related complications include pneumothorax, arrhythmia, venous air embolism, arterial injury, catheter-site infection, catheter vein stenosis, and catheter-related venous thrombosis.

The development of inhibitors or antibodies to the foreign protein or factor most frequently occurs in patients with undetectable factor activity. 

Deterrence and Patient Education

Patients and their families should receive comprehensive education about the nature of FXIII deficiency. Information should cover the potential symptoms, risk factors, and the importance of seeking prompt medical attention. Clinicians should emphasize that all patients must wear alert jewelry indicating their FXIII deficiency diagnosis, aiding emergency responders in providing appropriate care during unforeseen bleeding episodes.

Patients should be encouraged to enroll with tertiary care centers equipped to provide expert care at all times, particularly when facing uncontrolled bleeding episodes. Individuals with severe FXIII deficiency should be educated about various prophylactic strategies, especially if they have a history of intracranial bleeding. Encouraging adherence to preventative measures is essential to minimize the risk of severe bleeding episodes. Patients of childbearing age who are capable of becoming pregnant should receive counseling regarding pregnancy, addressing potential challenges, and minimizing the risk of fetal loss and hemorrhage during delivery. Although FXIII deficiency is rare, proactive measures in patient education, alert systems, and healthcare provider awareness are crucial. A collaborative approach ensures that individuals with FXIII deficiency receive optimal care and support, facilitating prevention and effective management of bleeding episodes.

Pearls and Other Issues

FXIII deficiency, a rare bleeding disorder, manifests with a normal coagulation profile, demanding a high level of suspicion for accurate diagnosis. Factors such as a strong family history of bleeding disorders, consanguineous marriage, recurrent early miscarriages, intracranial hemorrhage, delayed umbilical stump bleeding, or easy bruising and bleeding as a child begins to ambulate may all be indicative of FXIII deficiency.

The severity of bleeding generally corresponds with the severity of factor deficiency. Although a clot solubility test is commonly used for diagnosis, its sensitivity and specificity are limited, and variations exist between institutions. Quantitative assays are preferred screening methods, but their availability may be restricted in resource-constrained settings. Immunologic assays aid in diagnosing the condition. Treatment and prophylaxis for FXIII deficiency often involve the widespread use of cryoprecipitate, with recombinant FXIII also available for the same purpose. Acquired FXIII deficiency, though extremely rare, has been documented in older patients and those with multiple comorbidities, particularly autoimmune diseases.

Enhancing Healthcare Team Outcomes

In its activated form, FXIII plays a critical role in clot stabilization and cross-linking of the fibrin polymer, ensuring adequate hemostasis. Clinical manifestations of FXIII deficiency include delayed separation of the umbilical cord, bleeding from the umbilical stump in neonates, intracranial hemorrhage, poor wound healing, menorrhagia, hemarthrosis, and spontaneous miscarriages in early pregnancy. Diagnosis involves a stepwise approach, considering family history, responses to hemostatic challenges, and strategic laboratory testing. Treatment and prophylaxis often involve FFP, cryoprecipitate, or recombinant FXIII, but challenges include limited availability, high cost, infection risk, and administration-related risks.

FXIII deficiency can lead to various clinical manifestations, emphasizing the importance of early detection and comprehensive patient management. Specialized laboratory tests, including quantitative and immunological assays, are crucial for accurate diagnosis. Clinicians must navigate these complexities, promoting a multidisciplinary approach to enhance patient-centered care and optimize outcomes, patient safety, and team performance related to FXIII deficiency.

Details

Author

Ankit Mangla

Author

Hussein Hamad

Author

Robert B. Killeen

Editor:

Abhishek Kumar

Updated:

2/12/2024 6:52:06 PM

Feedback:

Send Us Your Comments

References

[1]

Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia : the official journal of the World Federation of Hemophilia. 2008 Nov:14(6):1190-200. doi: 10.1111/j.1365-2516.2008.01857.x. Epub     [PubMed PMID: 19141159]

[2]

Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood reviews. 2016 Nov:30(6):461-475. doi: 10.1016/j.blre.2016.06.002. Epub 2016 Jun 16     [PubMed PMID: 27344554]

[3]

Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie. 2014:34(2):160-6. doi: 10.5482/HAMO-13-08-0046. Epub 2014 Feb 7     [PubMed PMID: 24503678]

[4]

Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RA, Seifried E, Oldenburg J, Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thrombosis and haemostasis. 2007 Jun:97(6):914-21     [PubMed PMID: 17549292]

[5]

Yan MTS, Rydz N, Goodyear D, Sholzberg M. Acquired factor XIII deficiency: A review. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2018 Dec:57(6):724-730. doi: 10.1016/j.transci.2018.10.013. Epub 2018 Oct 30     [PubMed PMID: 30446212]

[6]

Kleber C, Sablotzki A, Casu S, Olivieri M, Thoms KM, Horter J, Schmitt FCF, Birschmann I, Fries D, Maegele M, Schöchl H, Wilhelmi M. The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing. Critical care (London, England). 2022 Mar 24:26(1):69. doi: 10.1186/s13054-022-03940-2. Epub 2022 Mar 24     [PubMed PMID: 35331308]

[7]

Alshehri FSM, Whyte CS, Mutch NJ. Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing. International journal of molecular sciences. 2021 Mar 17:22(6):. doi: 10.3390/ijms22063055. Epub 2021 Mar 17     [PubMed PMID: 33802692]

[8]

Watanabe H, Mokuda S, Tokunaga T, Kohno H, Ishitoku M, Araki K, Sugimoto T, Yoshida Y, Yamamoto T, Matsumoto M, Masumoto J, Hirata S, Sugiyama E. Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling. Inflammation and regeneration. 2023 Jan 6:43(1):2. doi: 10.1186/s41232-022-00252-4. Epub 2023 Jan 6     [PubMed PMID: 36609460]

[9]

Muszbek L, Bagoly Z, Cairo A, Peyvandi F. Novel aspects of factor XIII deficiency. Current opinion in hematology. 2011 Sep:18(5):366-72. doi: 10.1097/MOH.0b013e3283497e3e. Epub     [PubMed PMID: 21738029]

Level 3 (low-level) evidence

[10]

Karimi M, Peyvandi F, Naderi M, Shapiro A. Factor XIII deficiency diagnosis: Challenges and tools. International journal of laboratory hematology. 2018 Feb:40(1):3-11. doi: 10.1111/ijlh.12756. Epub 2017 Oct 13     [PubMed PMID: 29027765]

[11]

Schroeder V, Kohler HP. Factor XIII deficiency: an update. Seminars in thrombosis and hemostasis. 2013 Sep:39(6):632-41. doi: 10.1055/s-0033-1353392. Epub 2013 Aug 8     [PubMed PMID: 23929307]

[12]

Odame JE, Chan AK, Wu JK, Breakey VR. Factor XIII deficiency management: a review of the literature. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2014 Apr:25(3):199-205. doi: 10.1097/MBC.0000000000000029. Epub     [PubMed PMID: 24401950]

[13]

Nugent DJ. Prophylaxis in rare coagulation disorders -- factor XIII deficiency. Thrombosis research. 2006:118 Suppl 1():S23-8     [PubMed PMID: 16616323]

[14]

Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012 May 31:119(22):5111-7. doi: 10.1182/blood-2011-10-386045. Epub 2012 Mar 26     [PubMed PMID: 22451421]

[15]

Bouttefroy S, Meunier S, Milien V, Boucekine M, Chamouni P, Desprez D, Harroche A, Hochart A, Thiercelin-Legrand MF, Wibaut B, Chambost H, Rugeri L, CoDeC study group. Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort. British journal of haematology. 2020 Jan:188(2):317-320. doi: 10.1111/bjh.16133. Epub 2019 Aug 14     [PubMed PMID: 31414482]

Level 3 (low-level) evidence

[16]

Korte W. Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency? Journal of blood medicine. 2014:5():107-13. doi: 10.2147/JBM.S35395. Epub 2014 Jul 9     [PubMed PMID: 25031548]

[17]

Muszbek L, Katona É. Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. Seminars in thrombosis and hemostasis. 2016 Jun:42(4):429-39. doi: 10.1055/s-0036-1572326. Epub 2016 Apr 12     [PubMed PMID: 27071048]

[18]

Pelcovits A, Schiffman F, Niroula R. Factor XIII Deficiency: A Review of Clinical Presentation and Management. Hematology/oncology clinics of North America. 2021 Dec:35(6):1171-1180. doi: 10.1016/j.hoc.2021.07.009. Epub 2021 Oct 2     [PubMed PMID: 34607717]

[19]

Martinuzzo M, Barrera L, Altuna D, Baña FT, Bieti J, Amigo Q, D'Adamo M, López MS, Oyhamburu J, Otaso JC. Effects of Factor XIII Deficiency on Thromboelastography. Thromboelastography with Calcium and Streptokinase Addition is more Sensitive than Solubility Tests. Mediterranean journal of hematology and infectious diseases. 2016:8(1):e2016037. doi: 10.4084/MJHID.2016.037. Epub 2016 Aug 16     [PubMed PMID: 27648200]

[20]

Selby NM, Casula A, Lamming L, Mohammed M, Caskey F, Tackling AKI Investigators. Design and Rationale of 'Tackling Acute Kidney Injury', a Multicentre Quality Improvement Study. Nephron. 2016:134(3):200-204     [PubMed PMID: 27376867]

Level 2 (mid-level) evidence

[21]

Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, Asadi M, Jalalvand M, Shamsizadeh M. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology (Amsterdam, Netherlands). 2017 May:22(4):224-230. doi: 10.1080/10245332.2016.1263007. Epub 2016 Nov 28     [PubMed PMID: 27894217]

[22]

Duncan EM, Dale BJ, Lloyd JV. Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2014 Jun:25(4):340-8. doi: 10.1097/MBC.0000000000000037. Epub     [PubMed PMID: 24440916]

[23]

Dorgalaleh A, Tabibian S, Hosseini S, Shamsizadeh M. Guidelines for laboratory diagnosis of factor XIII deficiency. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2016 Jun:27(4):361-4. doi: 10.1097/MBC.0000000000000459. Epub     [PubMed PMID: 26588445]

[24]

Dorgalaleh A, Tabibian S, Hosseini MS, Farshi Y, Roshanzamir F, Naderi M, Kazemi A, Zaker F, Aghideh AN, Shamsizadeh M. Diagnosis of factor XIII deficiency. Hematology (Amsterdam, Netherlands). 2016 Aug:21(7):430-9. doi: 10.1080/10245332.2015.1101975. Epub 2016 Mar 30     [PubMed PMID: 27077776]

[25]

Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L, Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. Journal of thrombosis and haemostasis : JTH. 2011 Jul:9(7):1404-6. doi: 10.1111/j.1538-7836.2011.04315.x. Epub     [PubMed PMID: 22946956]

[26]

Dorgalaleh A, Assadollahi V, Tabibian S, Shamsizadeh M. Molecular Basis of Congenital Factor XIII Deficiency in Iran. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2018 Mar:24(2):210-216. doi: 10.1177/1076029616680473. Epub 2016 Nov 23     [PubMed PMID: 27879471]

[27]

Naderi M, Karimi M, Hosseini MS, Moradi EH, Shamsizadeh M, Dorgalaleh A. Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®. Iranian journal of pharmaceutical research : IJPR. 2016 Spring:15(2):635-40     [PubMed PMID: 27642336]

[28]

Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thrombosis research. 2012 Dec:130 Suppl 2():S12-4. doi: 10.1016/S0049-3848(13)70005-7. Epub     [PubMed PMID: 23439001]

[29]

Ashley C, Chang E, Davis J, Mangione A, Frame V, Nugent DJ. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia : the official journal of the World Federation of Hemophilia. 2015 Jan:21(1):102-8. doi: 10.1111/hae.12524. Epub 2014 Nov 7     [PubMed PMID: 25377187]

[30]

Lassila R. Clinical Use of Factor XIII Concentrates. Seminars in thrombosis and hemostasis. 2016 Jun:42(4):440-4. doi: 10.1055/s-0036-1572324. Epub 2016 Apr 12     [PubMed PMID: 27071044]

[31]

Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and haemostasis. 2018 Mar:118(3):451-460. doi: 10.1055/s-0038-1624581. Epub 2018 Feb 15     [PubMed PMID: 29448295]

[32]

Zanon E, Pasca S, Sottilotta G, Molinari AC, Ferretti A, Di Gregorio P, Pollio B, Pizzuti M, Notarangelo LD, Biasoli C, Cojutti P, Pea F, Simioni P, Peyvandi F. A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study. Blood transfusion = Trasfusione del sangue. 2023 Jul:21(4):350-355. doi: 10.2450/2022.0121-22. Epub 2022 Nov 18     [PubMed PMID: 36580025]

[33]

Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfusion medicine reviews. 2009 Jul:23(3):177-88. doi: 10.1016/j.tmrv.2009.03.001. Epub     [PubMed PMID: 19539873]

[34]

Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. British journal of anaesthesia. 2014 Dec:113(6):922-34. doi: 10.1093/bja/aeu158. Epub 2014 Jun 27     [PubMed PMID: 24972790]

[35]

Caudill JS, Nichols WL, Plumhoff EA, Schulte SL, Winters JL, Gastineau DA, Rodriguez V. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion. 2009 Apr:49(4):765-70. doi: 10.1111/j.1537-2995.2008.02021.x. Epub 2008 Dec 15     [PubMed PMID: 19192257]

[36]

Nilsson IM, Holmberg L, Stenberg P, Henriksson P. Characteristics of the factor VIII protein and Factor XIII in various factor VIII concentrates. Scandinavian journal of haematology. 1980 Apr:24(4):340-9     [PubMed PMID: 6774412]

[37]

Janbain M, Nugent DJ, Powell JS, St-Louis J, Frame VB, Leissinger CA. Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. Transfusion. 2015 Jan:55(1):45-50. doi: 10.1111/trf.12784. Epub 2014 Jul 29     [PubMed PMID: 25070582]

[38]

Asahina T, Kobayashi T, Okada Y, Itoh M, Yamashita M, Inamato Y, Terao T. Studies on the role of adhesive proteins in maintaining pregnancy. Hormone research. 1998:50 Suppl 2():37-45     [PubMed PMID: 9721590]

[39]

Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstetrical & gynecological survey. 2007 Apr:62(4):255-60     [PubMed PMID: 17371605]

Level 2 (mid-level) evidence

[40]

Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Shamsizadeh M, Bamedi T. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. International journal of hematology. 2014 Nov:100(5):443-9. doi: 10.1007/s12185-014-1664-1. Epub 2014 Sep 18     [PubMed PMID: 25230816]

[41]

Smith J, Bodine JS, Cunningham MT, Gooley K, Plapp FV, Dasgupta A, Ye Z. Perioperative therapeutic plasma exchange in a patient with rare Factor XIII inhibitor. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2023 Jun:62(3):103654. doi: 10.1016/j.transci.2023.103654. Epub 2023 Feb 9     [PubMed PMID: 36775674]